Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Study to Evaluate the Potential Impact of Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)

Next Previous
X
Search
Trial Profile

A Phase 3 Study to Evaluate the Potential Impact of Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 22 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Neflamapimod (Primary)
  • Indications Lewy body disease
  • Focus Registrational; Therapeutic Use
  • Sponsors CervoMed; EIP Pharma

    • Most Recent Events

    • 09 Oct 2020 New trial record
    • 06 Oct 2020 According to an EIP Pharma media release, based on the Phase 2 study (NCT04001517) results which demonstrate proof-of-concept of neflamapimod as a treatment for patients with DLB, the company plans to advance development of neflamapimod into Phase 3 study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top